FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2505964607> ?p ?o ?g. }

• W2505964607 endingPage "95" @default.
• W2505964607 startingPage "87" @default.
• W2505964607 abstract "Bone metastases from breast cancer are common, causing significant morbidity. Preclinical data of dasatinib, an oral small molecule inhibitor of multiple oncogenic tyrosine kinases, suggested efficacy in tumor control and palliation of bone metastases in metastatic breast cancer (MBC). This clinical trial aimed to determine whether treatment with either of 2 dose schedules of dasatinib results in a progression-free survival (PFS) >50 % at 24 weeks in bone metastasis predominant MBC, to evaluate the toxicity of the 2 dosing regimens, and explore whether treatment results in decreased serum bone turnover markers and patient-reported worst pain. Subjects with bone metastasis predominant MBC were randomly assigned to either 100 mg of dasatinib once daily, or 70 mg twice daily, with treatment continued until time of disease progression or intolerable toxicity. Planned accrual was 40 patients in each arm. The primary trial endpoint was PFS, defined as time from registration to progression or death due to any cause. Median PFS for all eligible patients (79) was 12.6 weeks (95 % CI 9.1-16.7). Neither cohort met the threshold for further clinical interest. There were no significant differences in PFS by randomized treatment arm (p = 0.85). Toxicity was similar in both cohorts, with no clear trend in serum biomarkers of bone turnover or patient-reported pain. Dasatinib was ineffective in controlling bone-predominant MBC in a patient population, unselected by molecular markers. Further study of dasatinib in breast cancer should not be pursued unless performed in molecularly determined patient subsets, or rational combinations." @default.
• W2505964607 created "2016-08-23" @default.
• W2505964607 creator A5008068115 @default.
• W2505964607 creator A5009523391 @default.
• W2505964607 creator A5018518463 @default.
• W2505964607 creator A5018617106 @default.
• W2505964607 creator A5035798552 @default.
• W2505964607 creator A5046583009 @default.
• W2505964607 creator A5056820426 @default.
• W2505964607 creator A5069748055 @default.
• W2505964607 creator A5070880815 @default.
• W2505964607 creator A5081974715 @default.
• W2505964607 date "2016-07-30" @default.
• W2505964607 modified "2023-10-17" @default.
• W2505964607 title "Phase II studies of two different schedules of dasatinib in bone metastasis predominant metastatic breast cancer: SWOG S0622" @default.
• W2505964607 cites W1534645474 @default.
• W2505964607 cites W1701849548 @default.
• W2505964607 cites W1768011742 @default.
• W2505964607 cites W1839333839 @default.
• W2505964607 cites W1909697168 @default.
• W2505964607 cites W1982659560 @default.
• W2505964607 cites W2000868207 @default.
• W2505964607 cites W2018131805 @default.
• W2505964607 cites W2033712867 @default.
• W2505964607 cites W2039677708 @default.
• W2505964607 cites W2041924766 @default.
• W2505964607 cites W2059552745 @default.
• W2505964607 cites W2061062195 @default.
• W2505964607 cites W2064201936 @default.
• W2505964607 cites W2088982930 @default.
• W2505964607 cites W2097667248 @default.
• W2505964607 cites W2103320273 @default.
• W2505964607 cites W2109561657 @default.
• W2505964607 cites W2111976640 @default.
• W2505964607 cites W2115813710 @default.
• W2505964607 cites W2117094074 @default.
• W2505964607 cites W2121576318 @default.
• W2505964607 cites W2129220952 @default.
• W2505964607 cites W2137654510 @default.
• W2505964607 cites W2139248078 @default.
• W2505964607 cites W2147545245 @default.
• W2505964607 cites W2158115107 @default.
• W2505964607 cites W2253228560 @default.
• W2505964607 cites W2316096113 @default.
• W2505964607 cites W2327350066 @default.
• W2505964607 cites W2599615113 @default.
• W2505964607 doi "https://doi.org/10.1007/s10549-016-3911-z" @default.
• W2505964607 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5021222" @default.
• W2505964607 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27475087" @default.
• W2505964607 hasPublicationYear "2016" @default.
• W2505964607 type Work @default.
• W2505964607 sameAs 2505964607 @default.
• W2505964607 citedByCount "29" @default.
• W2505964607 countsByYear W25059646072017 @default.
• W2505964607 countsByYear W25059646072018 @default.
• W2505964607 countsByYear W25059646072019 @default.
• W2505964607 countsByYear W25059646072020 @default.
• W2505964607 countsByYear W25059646072021 @default.
• W2505964607 countsByYear W25059646072022 @default.
• W2505964607 countsByYear W25059646072023 @default.
• W2505964607 crossrefType "journal-article" @default.
• W2505964607 hasAuthorship W2505964607A5008068115 @default.
• W2505964607 hasAuthorship W2505964607A5009523391 @default.
• W2505964607 hasAuthorship W2505964607A5018518463 @default.
• W2505964607 hasAuthorship W2505964607A5018617106 @default.
• W2505964607 hasAuthorship W2505964607A5035798552 @default.
• W2505964607 hasAuthorship W2505964607A5046583009 @default.
• W2505964607 hasAuthorship W2505964607A5056820426 @default.
• W2505964607 hasAuthorship W2505964607A5069748055 @default.
• W2505964607 hasAuthorship W2505964607A5070880815 @default.
• W2505964607 hasAuthorship W2505964607A5081974715 @default.
• W2505964607 hasBestOaLocation W25059646072 @default.
• W2505964607 hasConcept C121608353 @default.
• W2505964607 hasConcept C126322002 @default.
• W2505964607 hasConcept C143998085 @default.
• W2505964607 hasConcept C170493617 @default.
• W2505964607 hasConcept C203092338 @default.
• W2505964607 hasConcept C2775930923 @default.
• W2505964607 hasConcept C2776139714 @default.
• W2505964607 hasConcept C2776694085 @default.
• W2505964607 hasConcept C2777783956 @default.
• W2505964607 hasConcept C2779013556 @default.
• W2505964607 hasConcept C2779536868 @default.
• W2505964607 hasConcept C2780739268 @default.
• W2505964607 hasConcept C2908647359 @default.
• W2505964607 hasConcept C42362537 @default.
• W2505964607 hasConcept C530470458 @default.
• W2505964607 hasConcept C535046627 @default.
• W2505964607 hasConcept C71924100 @default.
• W2505964607 hasConcept C99454951 @default.
• W2505964607 hasConceptScore W2505964607C121608353 @default.
• W2505964607 hasConceptScore W2505964607C126322002 @default.
• W2505964607 hasConceptScore W2505964607C143998085 @default.
• W2505964607 hasConceptScore W2505964607C170493617 @default.
• W2505964607 hasConceptScore W2505964607C203092338 @default.
• W2505964607 hasConceptScore W2505964607C2775930923 @default.
• W2505964607 hasConceptScore W2505964607C2776139714 @default.
• W2505964607 hasConceptScore W2505964607C2776694085 @default.

• next